Caring Ambassadors Hepatitis C

Program Newsletter

www.HepCChallenge.org

June 2011

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 May;43(5):411-5.

http://www.ncbi.nlm.nih.gov/pubmed/21310673

 

Closure of Ascites Leaks with Fibrin Glue Injection in Patients with End-Stage Liver Disease. Sadik K, Laibstain S, Northup PG, Kashmer D, Bonatti HJ. J Laparoendosc Adv Surg Tech A. 2011 May 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21612447

 

Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/ emotional, and cognitive outcomes in children. Rodrigue JR, Balistreri W, Haber B, et al. Hepatology. 2011 May;53(5):1468-75. doi: 10.1002/hep.24248.

http://www.ncbi.nlm.nih.gov/pubmed/21351116

 

Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Shimokura G, Chai F, Weber DJ, et al. Infect Control Hosp Epidemiol. 2011 May;32(5):415-24.

http://www.ncbi.nlm.nih.gov/pubmed/21515970

 

Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Gen Hosp Psychiatry. 2011 May-Jun;33(3):232-7. Epub 2011 May 6.

http://www.ncbi.nlm.nih.gov/pubmed/21601719

 

Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

Patel K, Jhaveri R, George J, et al. J Viral Hepat. 2011 May;18(5):331-7. doi: 10.1111/j.1365-2893.2010.01310.x.

http://www.ncbi.nlm.nih.gov/pubmed/20367801

 

The hepatitis C self-management programme: a randomized controlled trial. Groessl EJ, Weingart KR, Stepnowsky CJ, Gifford AL, Asch SM, Ho SB. J Viral Hepat. 2011 May;18(5):358-68. doi: 10.1111/j.1365-2893.2010.01328.x.

http://www.ncbi.nlm.nih.gov/pubmed/20529203

 

Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Addiction. 2011 May;106(5):977-84. doi: 10.1111/j.1360-0443.2010.03347.x.

http://www.ncbi.nlm.nih.gov/pubmed/21205057

 

Diagnosis of depression in former injection drug users with chronic hepatitis C. Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 May-Jun;45(5):462-7.

http://www.ncbi.nlm.nih.gov/pubmed/21293293

 

Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment. Batki SL, Canfield KM, Ploutz-Snyder R. Am J Addict. 2011 Jul;20(4):312-8. doi: 10.1111/j.1521-0391.2011.00139.x. Epub 2011 May 31.

http://www.ncbi.nlm.nih.gov/pubmed/21679262

 

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Oze T, Hiramatsu N, Yakushijin T, et al. J Gastroenterol. 2011 May 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21538029

 

Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C. Tsunoda T, Inui A, Etani Y, et al. Hepatol Res. 2011 May;41(5):399-404. doi: 10.1111/j.1872-034X.2011.00789.x.

http://www.ncbi.nlm.nih.gov/pubmed/21518401

 

Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P. Eur J Gastroenterol Hepatol. 2011 May;23(5):375-81.

http://www.ncbi.nlm.nih.gov/pubmed/21502923

 

Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. J Gastroenterol Hepatol. 2011 May 18. doi: 10.1111/j.1440-1746.2011.06782.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21592230

 

Basic and Applied Science, Pre-Clinical Studies

 

T Helper Type 1/T Helper Type 17-Related Cytokines in Chronic Hepatitis C Patients before and after Interferon and Ribavirin Therapy. Fathy A, Ahmed AS, Metwally L, Hassan A. Med Princ Pract. 2011;20(4):345-9. Epub 2011 May 11.

http://www.ncbi.nlm.nih.gov/pubmed/21576995


 

 

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. El Awady MK, Anany MA, Esmat G, et al. J Gastroenterol Hepatol. 2011 May;26(5):843-50. doi: 10.1111/j.1440-1746.2010.06605.x.

http://www.ncbi.nlm.nih.gov/pubmed/21182542

 

Inhibition of Hepatitis C Virus 3a genotype entry through Glanthus Nivalis Agglutinin.

Ashfaq UA, Masoud MS, Khaliq S, Nawaz Z, Riazuddin S. Virol J. 2011 May 20;8:248.

http://www.ncbi.nlm.nih.gov/pubmed/21599979

 

Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Petrovic D, Stamataki Z, Dempsey E, et al. Hepatology. 2011 Jun;53(6):1846-53. doi: 10.1002/hep.24327. Epub 2011 May 2.

http://www.ncbi.nlm.nih.gov/pubmed/21452285

 

Expression profiles of genes associated with viral entry in HCV-infected human liver.

Nakamuta M, Fujino T, Yada R, et al. J Med Virol. 2011 May;83(5):921-7. doi: 10.1002/jmv.22042.

http://www.ncbi.nlm.nih.gov/pubmed/21412800

 

Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. Huang JF, Chuang YH, Dai CY, et al. Hepatol Res. 2011 May;41(5):430-436. doi: 10.1111/j.1872-034X.2011.00786.x. Epub 2011 Apr 19.

http://www.ncbi.nlm.nih.gov/pubmed/21504518

 

Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2. Coenen M, Nischalke HD, Krämer B, et al. Lab Invest. 2011 May 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21537327

 

Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Gragnani L, Piluso A, Giannini C, et al. Arthritis Rheum. 2011 May;63(5):1446-51. doi: 10.1002/art.30274.

http://www.ncbi.nlm.nih.gov/pubmed/21538321

 

Distinct Functions of NS5A in HCV RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. J Virol. 2011 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21593143

 

Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. Mo H, Yang C, Wang K, et al. J Viral Hepat. 2011 May;18(5):338-48. doi: 10.1111/j.1365-2893.2010.01314.x.

http://www.ncbi.nlm.nih.gov/pubmed/20456634

 

Inhibition of full length Hepatitis C Virus particles of 1a genotype through small interference RNA. Ansar M, Ashfaq UA, Shahid I, et al. Virol J. 2011 May 2;8:203.

http://www.ncbi.nlm.nih.gov/pubmed/21535893

 

HIV/HCV Coinfection

 

Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. Medrano J, Resino S, Vispo E, et al. J Viral Hepat. 2011 May;18(5):325-30. doi: 10.1111/j.1365-2893.2010.01309.x.

http://www.ncbi.nlm.nih.gov/pubmed/20456635

 

Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. Yoon JC, Crane PK, Ciechanowski PS, et al. AIDS Care. 2011 May 11:1-11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21562994

 

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. Pineda JA, Caruz A, di Lello FA, et al. AIDS. 2011 May 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21572301

 

Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. Rockstroh J, Teppler H, Zhao J, et al. HIV Med. 2011 May 22. doi: 10.1111/j.1468-1293.2011.00933.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21599819

 

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI, Soriano V, Naggie S, et al.  AIDS. 2011 May 15;25(8):1025-33.

http://www.ncbi.nlm.nih.gov/pubmed/21505315

 

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. Labarga P, Barreiro P, Mira JA, et al. AIDS. 2011 May 15;25(8):1131-3.

http://www.ncbi.nlm.nih.gov/pubmed/21537116

 

Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Vellozzi C, Buchacz K, Baker R, et al. J Viral Hepat. 2011 May;18(5):316-24. doi: 10.1111/j.1365-2893.2010.01299.x.

http://www.ncbi.nlm.nih.gov/pubmed/20367803

 

Treatment for hepatitis C virus with pegylated interferon-{alpha} plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. Masiá M, Robledano C, López N, Escolano C, Gutiérrez F. J Antimicrob Chemother. 2011 May 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21622971

 

Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection. Bruno R, Sacchi P, Cima S, et al. Dig Liver Dis. 2011 Jul;43(7):575-8. Epub 2011 May 19.

http://www.ncbi.nlm.nih.gov/pubmed/21596630

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 May;20(9-10):1215-24. doi: 10.1111/j.1365-2702.2010.03494.x. Epub 2011 Mar 3.

http://www.ncbi.nlm.nih.gov/pubmed/21371144

 

Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Arora S, Kalishman S, Dion D, et al. Health Aff (Millwood). 2011 Jun;30(6):1176-84. Epub 2011 May 19.

http://www.ncbi.nlm.nih.gov/pubmed/21596757

 

Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic hepatitis C patients. de Almeida CM, de Lima TA, Castro DB, et al. Scand J Immunol. 2011 May;73(5):486-95. doi: 10.1111/j.1365-3083.2011.02518.x.

http://www.ncbi.nlm.nih.gov/pubmed/21231952

 

Current strategies for managing providers infected with bloodborne pathogens. Turkel S, Henderson DK. Infect Control Hosp Epidemiol. 2011 May;32(5):428-34.

http://www.ncbi.nlm.nih.gov/pubmed/21515972

 

Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states.

Speers S, Klevens RM, Vonderwahl C, et al. Public Health Rep. 2011 May-Jun;126(3):344-8.

http://www.ncbi.nlm.nih.gov/pubmed/21553662

 

Breaking Bad News: The Patient's Viewpoint. Munoz Sastre MT, Sorum PC, Mullet E. Health Commun. 2011 May 17:1-7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21598151

 

Hepatitis C virus infection among adolescents and young adults --- Massachusetts, 2002--2009. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41.

http://www.ncbi.nlm.nih.gov/pubmed/21544042


 

 

Liver Cancer

 

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN. Int J Cancer. 2011 May 15;128(10):2344-52. doi: 10.1002/ijc.25585.

http://www.ncbi.nlm.nih.gov/pubmed/20669224

 

Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. World J Surg. 2011 May;35(5):1072-84.

http://www.ncbi.nlm.nih.gov/pubmed/21468888

 

Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C. Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. J Gastroenterol Hepatol. 2011 May 26. doi: 10.1111/j.1440-1746.2011.06785.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21615789